Stocksigma LogoStocksigma Logo

Accretion Pharmaceuticals Reports Strong H1 FY27 Growth with PAT Rising 72.6% YoY

Accretion Pharmaceuticals reported a 25.8% YoY increase in revenue from operations to ₹5,504.10 lakhs for the half-year ended 30th Sep'26, compared to

Accretion Pharmaceuticals Reports Strong H1 FY27 Growth with PAT Rising 72.6% YoY

Accretion Pharmaceuticals Ltd · Outcome · 31 Oct 2026, 6:24 pm

Accretion Pharmaceuticals Reports Strong H1 FY27 Growth with PAT Rising 72.6% YoY Accretion Pharmaceuticals reported a 25.8% YoY increase in revenue from operations to ₹5,504.10 lakhs for the half-year ended 30th Sep'26, compared to ₹4,373.62 lakhs in H1 FY26. Net profit surged 72.6% YoY to ₹820.14 lakhs from ₹475.22 lakhs, expanding basic EPS to ₹7.38 from ₹4.61. Profit before tax rose 69.2% YoY to ₹1,084.49 lakhs. Working capital build drove negative operating cash flow of ₹312.14 lakhs. Total net worth stood at ₹6,291.00 lakhs with closing cash equivalents of ₹212.67 lakhs as of 30th Sep'26.

Original exchange filing (PDF)

More announcements from Accretion Pharmaceuticals Ltd

All Accretion Pharmaceuticals Ltd announcements